Immunovant’s

Immunovant’s

Developing transformative therapies for autoimmune diseases with the goal of redefining outcomes for those affected by these conditions.

HQ location
New York City, United States
Launch date
Market cap
$2.7b
Enterprise value
$1.9b
Share price
$14.82 IMVT
Authorizing premium user...